

AMENDMENTS TO THE CLAIMS

1-53. (canceled)

54. (currently amended): A method of treating a subject before being treated with an anti-neoplastic ~~a neoplastic~~ agent in an amount sufficient to cause ~~a side effect selected from the group consisting of myelosuppression, mucositis and peripheral neuropathy,~~ which method comprises administering to said subject an amount of N-palmitoyl-S-[2(R,S),3-dilauroyloxypropyl]-(R)-cysteine (JBT 3002) in an amount sufficient to alleviate or prevent said mucositis ~~side effect~~.

55. (previously presented): The method of claim 54, wherein said JBT 3002 is encapsulated in liposomes.

56. (previously presented): The method of claim 55, wherein said liposomes are multilamellar liposomes.

57. (currently amended): A method to ~~ameliorate~~ alleviate a side effect of anti-neoplasia treatment in a subject, wherein said side effect is ~~myelosuppression, mucositis or peripheral neuropathy, which, and wherein said~~ subject is undergoing treatment with an anti-neoplasia agent, which method comprises administering to said subject a pharmaceutical composition comprising JBT 3002.

58. (previously presented): The method of claim 57, wherein said JBT 3002 is encapsulated in liposomes.

59. (previously presented): The method of claim 58, wherein said liposomes are multilamellar liposomes.

60. (currently amended): A method to ~~ameliorate~~ alleviate a side effect of anti-neoplasia treatment in a subject, wherein said side effect is ~~myelosuppression, mucositis or peripheral~~

~~neuropathy, which, and wherein said~~ subject has been treated with an anti-neoplasia agent, which method comprises administering to said subject a pharmaceutical composition comprising JBT 3002.

61. (previously presented): The method of claim 60, wherein said JBT 3002 is encapsulated in liposomes.

62. (previously presented): The method of claim 61, wherein said liposomes are multilamellar liposomes.

63. (new): The method of claim 54, wherein said JBT 3002 alleviates or prevents said mucositis by upregulating expression of endogenous IL-15.

64. (new): The method of claim 63, wherein said JBT 3002 is encapsulated in liposomes.

65. (new): The method of claim 64, wherein said liposomes are multilamellar liposomes.

66. (new): The method of claim 57, wherein said JBT 3002 alleviates said mucositis by upregulating expression of endogenous IL-15.

67. (new): The method of claim 66, wherein said JBT 3002 is encapsulated in liposomes.

68. (new): The method of claim 67, wherein said liposomes are multilamellar liposomes.

69. (new): The method of claim 60, wherein said JBT 3002 alleviates said mucositis by upregulating expression of endogenous IL-15.

70. (new): The method of claim 69, wherein said JBT 3002 is encapsulated in liposomes.

71. (new): The method of claim 70, wherein said liposomes are multilamellar liposomes.

72. (new): The method of claim 54, wherein said anti-neoplastic agent is CPT-11.

73. (new): The method of claim 57, wherein said anti-neoplastic agent is CPT-11.

74. (new): The method of claim 60, wherein said anti-neoplastic agent is CPT-11.